RxDoctor Payments Data

Brenda Chavez, MD

Family Medicine · Abilene, TXNPI 1427545474

Payments from drug & device makers

$1,448in general payments, 2019–2025

Across 70 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$437
  • AbbVie$373
  • Novo Nordisk$213
  • Exact Sciences$127
  • GSK$103
  • Octapharma USA, Inc.$39
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$1,448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,448 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,832
Medicare patients
107
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$86,156
JardianceEmpagliflozin34$32,729
TrulicityDulaglutide26$26,596
MounjaroTirzepatide23$24,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,704
JanuviaSitagliptin Phosphate22$21,182
FarxigaDapagliflozin Propanediol21$17,870
EliquisApixaban19$17,010
TradjentaLinagliptin18$16,883
LinzessLinaclotide31$16,444
SynjardyEmpagliflozin/Metformin Hcl13$15,100
Tresiba Flextouch U-100Insulin Degludec27$13,456
BelsomraSuvorexant13$6,082
Spiriva RespimatTiotropium Bromide11$5,769
Gabapentin177$2,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$213$86,15679 claims
GSKTrelegy Ellipta$103$23,70427 claims
AstraZenecaFarxiga$437$17,87021 claims
PfizerEliquis$18$17,01019 claims
AbbVieLinzess$373$16,44431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →